Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Contag, Caitlin A. ; Mische, Leah ; Fong, Isabel ; Karan, Abraar ; Vaidya, Akanksha ; McCormick, David W. ; Bower, William ; Hacker, Jill K. ; Johnson, Kelly ; SanJuan, Perla ; Crebbin, Linda ; Temmins, Caroline ; Sahni, Harleen ; Bogler, Yael ; Cooper, Joseph D. ; Narasimhan, Supriya
• Description:
  Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.
• Subjects:
  Dispatch Expedited Treatment Of Mpox With Suspected Tecovirimat Resistance In Immunocompromised Patient, United States, 2022
• Keywords:
  Antiviral Drug Benzamides Disease Outbreaks Drug Resistance HIV/AIDS Human Immunodeficiency Virus Humans Immunocompromised Host Monkeypox Monkeypox Virus Mpox Mpox (monkeypox) MPX MPXV Severe Infection Tecovirimat Tecovirimat Resistance United States Viruses

  More +
• Source:
  Emerg Infect Dis. 2023; 29(12):2520-2523
• Pubmed ID:
  37856215
• Pubmed Central ID:
  PMC10683816
• Document Type:
  Journal Article
• Funding:
  U01 CK000539/CK/NCEZID CDC HHSUnited States/ ; U01CK000539/ACL/ACL HHSUnited States/
• Volume:
  29
• Issue:
  12
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:2f0743ea7f75826168d89d50119efae467295f71d10facfd636d20dd8881d724
• Download URL:
  https://stacks.cdc.gov/view/cdc/138531/cdc_138531_DS1.pdf
• File Type:
  [PDF - 4.53 MB ]